Peter C. Black MD, FRCSC, FACS
Professor, Department of Urologic Sciences, University of British Columbia; Khosrowshahi Family Chair in Bladder Cancer Research; Senior Research Scientist, Vancouver Prostate Centre; Vancouver, BC, CanadaPeter Black is a Urologic Oncologist at Vancouver General Hospital, a Senior Research Scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia. He completed his urologic training at the University of Washington in Seattle and fellowship in Urologic Oncology at M.D. Anderson Cancer Center in Houston, Texas. He has a clinical subspecialty interest in prostate and bladder cancer and also a translational research program related primarily to bladder cancer. He is inaugural Editor-in-Chief of the SIU Journal.
Disclosures
Dr. Black reports the following:- Member of an advisory board or equivalent with a commercial organization:
- AbbVie, AstraZeneca, Astellas, Bayer, Biosyent, BMS, EMD-Serono, Ferring, Fergene, H3-Biomedicine, Janssen, Merck, Protara Therapeutics, QED Bioscience, Roche, Sanofi, Sesen Bio, TerSera
- Member of a speakers bureau:
- AbbVie, Biosyent, Janssen, Ferring, TerSera, Pfizer
- Recipient of grant(s) or an honorarium from a commercial organization:
- iProgen, Sanofi, Bayer
- Currently participating in or have participated in a clinical trial within the past two years:
-
- Genentech, Janssen, BMS, Astellas, Sitka, MDx Health, AstraZeneca, Therelase, Pacific Edge
- Shares a patent with (but have received no royalties from):
- Decipher Biosciences
Recent Contributions to PracticeUpdate:
- Factors Associated With Deferred Treatment in Patients With Low-Risk Prostate Cancer
- Finasteride Efficacy in Bladder Cancer by Patient Race/Ethnicity
- Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
- Survival and Health Costs for Patients With Advanced Bladder Cancer